Revelation Biosciences Reports $2.1 Million Net Loss and Decrease in Total Assets

Revelation Biosciences, Inc. reported a net loss of $2.1 million for the three months ended March 31, 2025, a decrease from a net loss of $2.7 million during the same period in 2024. The company’s total operating expenses increased to $2.1 million, up from $1.9 million year-over-year, primarily driven by higher research and development costs, which rose to $858,830 from $717,582. General and administrative expenses also saw a slight increase, totaling $1.2 million compared to $1.2 million in the prior year. The company has not generated any revenue since its inception and continues to face significant operating losses.

As of March 31, 2025, Revelation Biosciences had total assets of $3.97 million, a significant decrease from $6.62 million at the end of 2024. The decline in assets was largely attributed to a reduction in cash and cash equivalents, which fell to $3.7 million from $6.5 million. The company’s stockholders’ equity also decreased to $2.88 million from $4.71 million, reflecting the ongoing losses and the impact of a reverse stock split executed on January 28, 2025. The number of shares outstanding increased to 963,796 from 522,223 due to this reverse stock split and other equity transactions.

In terms of operational developments, Revelation is focused on advancing its proprietary formulation, Gemini, which is being evaluated for multiple therapeutic applications, including acute kidney injury and chronic kidney disease. The company has reported an increase in clinical study expenses related to its product candidates, indicating a commitment to advancing its research and development efforts. However, the company has expressed concerns regarding its liquidity, stating that its current cash reserves may not be sufficient to sustain operations for the next year without additional capital.

Looking ahead, Revelation Biosciences plans to seek additional funding through public or private equity or debt financing to support its ongoing research and development activities. The company acknowledges the uncertainty surrounding its ability to raise capital on favorable terms, which could impact its operational capabilities and future product development. The management has indicated that without successful fundraising, it may be forced to delay or reduce its research and development programs, which could adversely affect its business operations and growth prospects.